Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide

REFERENCES

• Cobb S, Anderson F, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953;249:553–6.
   Google Scholar
• Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM 3rd, Themeau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583–7.
   PubMed Web of Science ®Google Scholar
• Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol. 2004;69: 3–8.
   Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46:2287–93.
   Google Scholar
• Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression. J Immunol. 1999;162: 2095–102.
   PubMed Web of Science ®Google Scholar
• Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with lefluno-mide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159:2542–50.
   Google Scholar
• Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with pla-cebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999;353:259–66.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, American College of Rheumatology, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheuma-toid arthritis. Arthritis Rheum. 2008;59:762–84.
   Google Scholar
• Knevel R, Schoels M, Huizinga TW, Aletaha D, Burmester GR, Combe B, et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:987–94.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associa-tions with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54: 628–34.
   Google Scholar
• Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol. 1991;18:188–94.
   PubMed Web of Science ®Google Scholar
• van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994;53: 224–8.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294–300.
   PubMed Web of Science ®Google Scholar
• van Albada-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, et al. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoar-thritis or soft tissue rheumatism. Arthritis Rheum. 1988;31: 667–71.
   Google Scholar
• Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum. 1991;21:1–11.
   PubMed Web of Science ®Google Scholar
• Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse effects. Am J Med. 1994;96:115-23. Springer
   Google Scholar
• Segal BH, Sneller MC. Life-threatening complications of auto-immune disease: infections complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am. 1997;23:220–37.
   Web of Science ®Google Scholar
• Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34:2201–3.
   Google Scholar
• Savage RL, Highton J, Boyd IW, Chapman P. Pneumonitis associated with leflunomide: a profile of New Zealand and Aus-tralian reports. Intern Med J. 2006;36:162–9.
   PubMed Web of Science ®Google Scholar
• Grover R, Dhir V, Aneja R, Arya V, Galle A, Marwaha V, et al. Severe infections following leflunomide therapy for rheumatoid arthritis. Rheumatology (Oxford). 2006;45:918–20.
   PubMed Web of Science ®Google Scholar
• Bruyn GA, Jansen TL, Ten Brinke A, De Vries M, Houtman PM, van Roon EN. Cavitating pneumonia, a severe complication of leflunomide therapy in chronic polyarthritis. Rheumatology (Oxford). 2007;46:553–4.
   Google Scholar
• Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheuma-toid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34:706–11.
   PubMed Web of Science ®Google Scholar
• Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:341–2.
   PubMed Web of Science ®Google Scholar
• Boerbooms AM, Kerstens PJ, van Loenhout JW, Mulder J, van de Putte LB. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum. 1995;24:411–21.
   Google Scholar
• Hernández-Cruz B, Sifuentes-Osornio J, Ponce-de-Leon Rosales S, Ponce-de-Lek Garduilo A, Diaz-Jouanen E. Mycobacterium tuberculosis infection in patients with systemic rheumatic dis-eases. A case-series. Clin Exp Rheumatol. 1999;17:289–96.
   PubMed Web of Science ®Google Scholar
• Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheu-matoid arthritis. Arthritis Rheum. 1970;13:125–30.
   PubMed Web of Science ®Google Scholar
• Abruzzo JL. Rheumatoid arthritis and mortality. Arthritis Rheum. 1982;25:1020–3.
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective followup. J Rheumatol. 1984;11: 158–61.
   Google Scholar
• Cosh JA. Survival and death in rheumatoid arthritis. J Rheumatol. 1984;11:117–9.
   PubMedGoogle Scholar
• Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T, Study Committee for Leflunomide-induced Lung Injury, Japan College of Rheumatology, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48: 1265–8.
   Google Scholar